B-SOFT's share price drop may be linked to its shift into a loss-making position. Last year's performance suggests unresolved challenges, worse than the annualised loss of 8% over the last half decade. Investors should ensure they're buying a high-quality business, even in a falling market.
B-SOFTLtd's falling ROCE and sales, coupled with rising capital employment, suggest a potential loss in competitive edge or market share. A positive shift in these metrics is needed for it to remain a viable investment.
Investors' skepticism about B-SOFTLtd's strong revenue growth prospects may be causing its low P/S ratio. Despite forecasted growth, the market questions these estimates, anticipating future revenue volatility.
The continuous decline in B-SOFTLtd's ROCE despite increasing capital coupled with falling revenue is worrying. Persisting trends may indicate a firm losing market share while trying to reinvest for growth. Exploring other investment opportunities could be wise if these trends endure.
Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry. Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry.
B-Soft Co.,Ltd. Stock Forum
$MICROPORT (00853.HK)$ $WEIGAO GROUP (01066.HK)$ $CSPC PHARMA (01093.HK)$ $SINOPHARM (01099.HK)$ $CR MEDICAL (01515.HK)$ $CONSUN PHARMA (01681.HK)$ $CHUNLI MEDICAL (01858.HK)$ $UNI MEDICAL (02666.HK)$ $HENLIUS (02696.HK)$ $B-Soft Co.,Ltd. (300451.SZ)$ $Guangxi LiuYao Group (603368.SH)$ $BEIGENE (06160.HK)$
$BEIGENE (06160.HK)$ $CSPC PHARMA (01093.HK)$ $HENLIUS (02696.HK)$ $MICROPORT (00853.HK)$ $WEIGAO GROUP (01066.HK)$ $SINOPHARM (01099.HK)$ $CR MEDICAL (01515.HK)$ $CONSUN PHARMA (01681.HK)$ $CHUNLI MEDICAL (01858.HK)$ $UNI MEDICAL (02666.HK)$ $HENLIUS (02696.HK)$ $B-Soft Co.,Ltd. (300451.SZ)$ $Guangxi LiuYao Group (603368.SH)$ $BEIGENE (06160.HK)$
No comment yet